Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
16
02
2022
accepted:
12
05
2022
revised:
12
05
2022
pubmed:
24
6
2022
medline:
28
10
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
Serotonin producing pancreatic neuroendocrine tumors (SP-PanNET) account for 0.58-1.4% of all pancreatic neuroendocrine tumors (PanNET). They may present with atypical symptoms, such as acute pancreatitis and are often radiologically characterized by main pancreatic duct dilatation. SP-PanNET are well differentiated neuroendocrine tumors (NET) distinct from classical PanNET by atypical serotonin secretion and abundant dense stroma deposition, like serotonin producing ileal NET leading in some cases to difficulties to reliably distinguish SP-PanNET from ileal NET metastases. The biology and molecular profile of SP-PanNET remain poorly characterized and the cell of origin within the pancreas is unclear. To address these questions, we analyzed a large cohort of SP-PanNET by immunohistochemistry (n = 29; ATRX, DAXX, MENIN, Islet1, PAX6, PDX1, ARX, CDX2), whole genome copy number array (Oncoscan™) and a large NGS panel (NovoPM™) (n = 10), FISH (n = 13) and RNA sequencing (n = 24) together with 21 ileal NET and 29 nonfunctioning PanNET (NF-PanNET). These analyses revealed a unique genomic profile with frequent isolated loss of chromosome 1 (14 cases-61%) and few pathogenic mutations (KMT2C in 2 cases, ARID1A in 1 case). Unsupervised RNAseq-based clustering showed that SP-PanNET were closer to NF-PanNET than ileal NET with an exclusive beta cell-like signature. SP-PanNET showed TGF-β pathway activation signatures associated with extracellular matrix remodeling and similar signature were reproduced in vitro when pancreatic stellate cells were exposed to serotonin. SP-PanNET immunohistochemical profile resemble that of ileal NET except for PDX1 and PAX6 expression to a lesser extend suggesting that these two markers may be useful to diagnose SP-PanNET. Taken together, this suggests that SP-PanNET are a very specific PanNET entity with a peculiar biology leading to the characteristic fibrotic aspect.
Identifiants
pubmed: 35739266
doi: 10.1038/s41379-022-01110-x
pii: S0893-3952(22)00238-1
doi:
Substances chimiques
Serotonin
333DO1RDJY
Transforming Growth Factor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1713-1722Informations de copyright
© 2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Peart, W. S., Porter, K. A., Robertson, J. I., Sandler, M. & Baldock, E. Carcinoid syndrome due to pancreatic-duct neoplasm secreting 5-hydroxytryptophan and 5-hydroxytryptamine. Lancet 1, 239–243 (1963).
Modlin, I. M., Lye, K. D. & Kidd, M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97, 934–959 (2003).
Lloyd, R. V., Osamura, R. Y., Kloppel, G. & Rosai, J. WHO Classification of Tumours of Endocrine Organs. 4th Edition (2017).
Kalhor, N., Suster, S. & Moran, C. A. Primary Sclerosing Neuroendocrine Carcinomas of the Lung: A Clinicopathologic and Immunohistochemical Study of 10 Cases. Am. J. Clin. Pathol. 133, 618–622 (2010).
Burgio, M. D. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome. Eur. Radiol. 11, 8671-8681 (2021).
Kawamoto, S., Shi, C., Hruban, R. H., Choti, M. A., Schulick, R. D., Fishman, E. K. et al. Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. Am. J. Roentgenol. 197, W482–W488 (2011).
Scott, A. T., Pelletier, D., Maxwell, J. E., Sherman, S. K., Keck, K. J., Li, G. et al. The pancreas as a site of metastasis or second primary in patients with small bowel neuroendocrine tumors. Ann. Surg. Oncol. 26, 2525–2532 (2019).
Australian Pancreatic Cancer Genome Initiative, Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543, 65–71 (2017).
Scarpa, A. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Annales d’Endocrinologie 80, 153–158 (2019).
La Rosa, S., Franzi, F., Albarello, L., Schmitt, A., Bernasconi, B., Tibiletti, M. G. et al. Serotonin-producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors. Pancreas 40, 883–895 (2011).
Blažević, A., Hofland, J., Hofland, L. J., Feelders, R. A. & de Herder, W. W. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat. Cancer 25, R115–R130 (2018).
Bader, M. Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol. Ther. 205, 107423 (2020).
Dolivo, D. M., Larson, S. A. & Dominko, T. Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis. Cell. Mol. Life Sci. 75, 3663–3681 (2018).
Zhang, J., Cui, R., Feng, Y., Gao, W., Bi, J., Li, Z. et al. Serotonin exhibits accelerated bleomycin-induced pulmonary fibrosis through tph1 knockout mouse experiments. Med. Inflamm. 2018, 1–10 (2018).
Oga, T., Matsuoka, T., Yao, C., Nonomura, K., Kitaoka, S., Sakata, D. et al. Prostaglandin F2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β. Nat. Med. 15, 1426–1430 (2009).
Laskaratos, F., Rombouts, K., Caplin, M., Toumpanakis, C., Thirlwell, C. & Mandair, D. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer 123, 4770–4790 (2017).
Johnson, A., Wright, J. P., Zhao, Z., Komaya, T., Parikh, A., Merchant, N. et al. Cadherin 17 is frequently expressed by ‘sclerosing variant’ pancreatic neuroendocrine tumour. Histopathology 66, 225–233 (2015).
Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-β signaling in fibrosis. Growth Factors 29, 196–202 (2011).
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S. & Derynck, R. TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities. J. Pathol. 254, 358–373 (2021).
McCall, C. M., Shi, C., Klein, A. P., Konukiewitz, B., Edil, B. H., Ellison, T. A. et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Human Pathology 43, 1169–1176 (2012).
Inzani, F., Petrone, G. & Rindi, G. The new world health organization classification for pancreatic neuroendocrine neoplasia. Endocrinol. Metab. Clin. North Am. 47, 463–470 (2018).
Piqueret‐Stephan, L., Marcaillou, C., Reyes, C., Honoré, A., Letexier, M., Gentien, D. et al. Massively parallel DNA sequencing from routinely processed cytological smears. Cancer Cytopathol. 124, 241–253 (2016).
1000 Genomes Project Consortium, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
Kircher, M., Witten, D. M., Jain, P., O’Roak, B. J., Cooper, G. M. & Shendure, J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
Jagadeesh, K. A., Wenger, A. M., Berger, M. J., Guturu, H., Stenson, P. D., Cooper, D. N. et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat. Genet. 48, 1581–1586 (2016).
Metsalu, T. & Vilo, J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 43, W566-570 (2015).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Froeling, F. E. M., Mirza, T. A., Feakins, R. M., Seedhar, A., Elia, G., Hart, I. R. et al. Organotypic Culture Model of Pancreatic Cancer Demonstrates that Stromal Cells Modulate E-Cadherin, β-Catenin, and Ezrin Expression in Tumor Cells. Am. J. Pathol. 175, 636–648 (2009).
Guedj, N., Blaise, L., Cauchy, F., Albuquerque, M., Soubrane, O. & Paradis, V. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod Pathol 34, 408–416 (2021).
Soga,J., Tazawa, K. Pathologic analysis of carcinoids Histologic reevaluation of 62 cases. Cancer. 28, 990-8 (1971).
Pea, A., Yu, J., Marchionni, L., Noe, M., Luchini, C., Pulvirenti, A. et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann. Surg. 271, 566–573 (2020).
Wang, H., Bender, A., Wang, P., Karakose, E., Inabnet, W. B., Libutti, S. K. et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. Nat. Commun. 8, 767 (2017).
Cho, S.-J., Yoon, C., Lee, J. H., Chang, K. K., Lin, J., Kim, Y.-H. et al. KMT2C Mutations in diffuse-type gastric adenocarcinoma promote epithelial-to-mesenchymal transition. Clin. Cancer Res. 24, 6556–6569 (2018).
Chen, X., Zhang, G., Chen, B., Wang, Y., Guo, L., Cao, L. et al. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomed. Pharmacother. 116, 108997 (2019).
Ishida, S., Akita, M., Fujikura, K., Komatsu, M., Sawada, R., Matsumoto, H. et al. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study. Human Pathol. 110, 1–10 (2021).
Almaça, J., Molina, J., Menegaz, D., Pronin, A. N., Tamayo, A., Slepak, V. et al. Human beta cells produce and release serotonin to inhibit glucagon secretion from alpha cells. Cell Reports 17, 3281–3291 (2016).
Makhmutova, M., Weitz, J., Tamayo, A., Pereira, E., Boulina, M., Almaça, J. et al. Pancreatic β-cells communicate with vagal sensory neurons. Gastroenterology 160, 875-888. e11 (2021).
Moon, J. H., Kim, H., Kim, H., Park, J., Choi, W., Choi, W. et al. Lactation improves pancreatic β cell mass and function through serotonin production. Sci. Transl. Med. 12, eaay0455 (2020).
Onaitis, M. W., Kirshbom, P. M., Hayward, T. Z., Quayle, F. J., Feldman, J. M., Seigler, H. F. et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann. Surg. 232, 549–556 (2000).
Tacha, D., Qi, W., Zhou, D., Bremer, R. & Cheng, L. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin. Appl. Immunohistochem. Mol. Morphol. 21, 59–63 (2013).